Comparison · NCT03120949-deaths
Treatment Arm 1: OKZ 64 mg q4w + MTX vs Treatment Arm 2: OKZ 64 mg q2w + MTX: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Treatment Arm 1: OKZ 64 mg q4w + MTX vs Treatment Arm 2: OKZ 64 mg q2w + MTX: deaths from any cause. Trial comparisons, record NCT03120949-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03120949-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0125 | 0.0073 | 0.0212 | wilson | |
| Risk in group 2 | 0.0123 | 0.00717 | 0.0209 | wilson | |
| Risk difference, group 1 minus group 2 | 0.000211 | -0.00982 | 0.0103 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.02 | 0.474 | 2.18 | log | |
| Odds ratio, group 1 over group 2 | 1.02 | 0.469 | 2.21 | log | |
| Number needed to harm, for one more death from any cause on Treatment Arm 1: OKZ 64 mg q4w + MTX than on Treatment Arm 2: OKZ 64 mg q2w + MTX | 4,730 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Treatment Arm 1: OKZ 64 mg q4w + MTX | Olokizumab 64 mg SC q4w + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular).~Olokizumab 64 mg SC q4w: 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS). PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL. | 13 | 1,043 | EG000 |
| Group 2 | Treatment Arm 2: OKZ 64 mg q2w + MTX | Olokizumab 64 mg SC q2w + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular).~Olokizumab 64 mg SC q2w: 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS). PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL. | 13 | 1,061 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
Adverse events (AEs) and serious adverse events (SAEs) were reported from OLE Baseline (the same visit as the Week 24 visit in the core studies) until the end of the follow-up period (safety follow-up (SFU-3)). Any AE, including any AE still ongoing at the end of the study, was to be followed until it had resolved, it had a stable sequelae, the Investigator determined that it was no longer clinically significant, or the subject was lost to follow-up.
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
- NCT number
- NCT03120949
- Phases
- PHASE3
- Conditions
- Rheumatoid Arthritis
- Interventions
- Olokizumab 64 mg SC q4w, Olokizumab 64 mg SC q2w, Concomitant treatment
- Lead sponsor
- R-Pharm International, LLC
- Results first posted
- 2022-06-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03120949?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03120949-deaths